Where does Iovance Biotherapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Iovance Biotherapeutics, Inc. ranks #3,924 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Iovance Biotherapeutics, Inc. hold?

Iovance Biotherapeutics, Inc. holds 92 US utility patents granted between 2018 and 2025, spanning 9 technology areas.

What is Iovance Biotherapeutics, Inc.'s Innovation Score?

Iovance Biotherapeutics, Inc. has an Innovation Score of 48.2 out of 100 (top 17% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Iovance Biotherapeutics, Inc.'s patent grant rate increasing or decreasing?

Iovance Biotherapeutics, Inc.'s recent grant velocity is +733% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Iovance Biotherapeutics, Inc.'s patents?

Iovance Biotherapeutics, Inc.'s patents average 22.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Iovance Biotherapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Iovance Biotherapeutics, Inc.

Q: What technology areas does Iovance Biotherapeutics, Inc. focus on?

Iovance Biotherapeutics, Inc.'s top technology area is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes) with 91 patents. Grants appear in 9 CPC subclasses total.

USPTO PatentsView assignee record - 92 granted patents across 9 technology areas, recorded in grant years 2018–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Iovance ranks #3,924 of 49,997 tracked US assignees by granted-patent volume, with 92 patents across 9 technology areas.

#3,924
of 49,997 US assignees by volume: Top 17%
by Innovation Score (48.2/100): 22.0
avg claims per patent: +733%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R3924 · US Corporation #3,924 · 92 grants

GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 92 grants
TOP-DECILE #3,924/49,997
PHOTO-FINISH Hubei Yangtze…
CPC-NARROW A61K · 9 areas
INNOV-PAR 48.2/100
CLAIMS-DENSE 22.0 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +733% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Hubei Yangtze Industrial Innovation Center Of Advanced Display Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Aktiebolaget… · near

48
Blackhawk Network · near

48
Eurokera S N C · near

48
Iovance Biotherapeut… · this assignee

48
Jiangsu Favored… · near

48
3D Lighting… · lowest

7

What this shows Iovance's Innovation Score is 48.2/100 (top 17% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Iovance's grants concentrate

Iovance Biotherapeutics, Inc. is a focused PatentsView assignee: 9 CPC subclasses with 98.9% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2022 (26 grants) versus a trough of 1 in 2018. By volume, Iovance sits between Hubei Yangtze Industrial Innovation Center Of Advanced Display Co., Ltd. and Lindsay Corporation.

Iovance's three-year grant acceleration

From 2019–2021 to 2022–2024, Iovance Biotherapeutics, Inc. moved from 36 to 47 grants (1.31x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Hubei Yangtze Ind…

92
Hyster-yale Group

92
Institut National…

92
Innovelis

92
Kraton Polymers

92
LAT Enterprises

92
Lippert Components

92
Lindsay

92
Iovance Biotherap… ◀

92

What this shows Iovance holds 92 patents at rank #3,924, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Iovance

By rank, the assignees closest to #3,924 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Iovance's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Iovance, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (48 here).

Blackhawk Network, Inc. 48 Aktiebolaget Electrolux 48 Eurokera S.N.C. 48 Jiangsu Favored Nanotechnology Co., Ltd. 48

Similar claim depth

Nearest assignees by average claims per patent (22.0 here).

Avalara, Inc. 22.0 avg NxGen Partners IP, LLC 22.0 avg Handylab, Inc. 22.0 avg Novomer, Inc. 22.0 avg

Iovance's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

48 Top 17% higher than 83% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table

Iovance Biotherapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2018	1	1.1%
2019	8	8.7%
2020	5	5.4%
2021	23	25.0%
2022	26	28.3%
2023	6	6.5%
2024	15	16.3%
2025partial year	8	8.7%

Which technologies does Iovance Biotherapeutics, Inc. patent most?

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 91

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 91

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 84

A01N - Preservation OF Bodies OF Humans OR Animals OR Plants OR Parts Thereof ; Biocides, e.g. AS Disinfectants, AS Pesticides OR AS Herbicides ; Pest Repellants OR ATTRACTANTS; Plant Growth Regulators 71

C07K - Peptides 26

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 23

G06Q - Information AND Communication Technology [ICT] Specially Adapted FOR Administrative, Commercial, Financial, Managerial OR Supervisory PURPOSES; Systems OR Methods Specially Adapted FOR Administrative, Commercial, Financial, Managerial OR Supervisory Purposes, NOT Otherwise Provided FOR 5

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 5

C12M - Apparatus FOR Enzymology OR MICROBIOLOGY; Apparatus FOR Culturing Microorganisms FOR Producing Biomass, FOR Growing Cells OR FOR Obtaining Fermentation OR Metabolic Products, i.e. Bioreactors OR Fermenters 2

Top 9 of 9 technology areas

Where it ranks

Overall rank by patents

#3,924

of 49,997 tracked assignees

Innovation Score

48.2 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Iovance Biotherapeutics, Inc.'s patent record in context - here's where to go next.

Iovance Biotherapeutics, Inc.'s lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 98.9% of its portfolio - see every assignee active in that class. Explore A61K
Ranked #3,924 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Iovance Biotherapeutics, Inc. against Hubei Yangtze Industrial Innovation Center Of Advanced Display Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 48.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.